Grants and Contributions:

Back to search

Title:

UK Biomanufacturing - 10143578 - NPmsDNA2024 - Development of in vivo targeted non-viral gene therapies

Agreement Number:

1034675

Agreement Value:

$63,380.00

Agreement Date:

Jan 1, 2027 - Mar 26, 2027

Description:

As part of the international consortium project “UK Biomanufacturing - 10143578 - NPmsDNA2024 - Development of in vivo targeted non-viral gene therapies”, this project's objective is to use Chromatin Bio's bioinformatics platform to design novel gene regulatory elements, improving gene expression in Mediphage therapeutic constructs for Stargardt disease, while reducing sequence complexity and increasing manufacturing yields. Once generated, these constructs will be complexed with Entos proprietary ocular nanocarrier for in vivo evaluation by NRC and Entos. The best performing candidates will then be manufactured as msDNA drug substances for further therapeutic development.

Organization:

National Research Council Canada

Expected Results:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Location:

Toronto, Ontario, CA M5G 0B7

Reference Number:

172-2025-2026-Q2-1034675

Agreement Type:

Contribution

Report Type:

Grants and Contributions

Recipient Business Number:

788308328

Recipient Type:

For-profit organization

Recipient's Operating Name:

Mediphage Bioceuticals, Inc.

Recipient's Legal Name:

Mediphage Bioceuticals, Inc.

Federal Riding Name:

University--Rosedale

Federal Riding Number:

35110

Program:

Industrial Research Assistance Program – Contributions to Firms

Program Purpose:

Coverage:

IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.

NAICS Code:

54171